DTIL (Precision BioSciences) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DTIL Precision BioSciences Inc DTIL
50 GF Score
Price $8.85
GF Value $1.82
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Net Loan?

Net Loan only applies to banks and insurance companies.

DTIL
50GF Score
Precision BioSciences Inc DTIL
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.85 is trading 386.3% above its estimated GF Value™ of $1.82. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

  • Net Loan:
  • GF Value™: $1.82 vs. price of $8.85 (386.3% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Precision BioSciences Business Description

Other Exchanges PBS0:Germany
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score

Get the complete analysis for DTIL

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.85
Price
$1.82
GF Value